Thrombin activatable fibrinolysis inhibitor activation and bleeding in haemophilia A

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Haemophilia

• Publication date

  2012-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1365-2516.2011.02648.xPMID 21933309PMCID PMC3289731
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Challenges of multiple mutations in individual patients with haemophilia

  2011cited by this paper
• Factor V Leiden and hemophilia.

  2010cited by this paper
• Discordant fibrin formation in hemophilia

  2009cited by this paper
• Thrombin generation and bleeding in haemophilia A

  2009cited by this paper
• Soluble thrombomodulin partially corrects the premature lysis defect in FVIII‐deficient plasma by stimulating the activation of thrombin activatable fibrinolysis inhibitor

  2009cited by this paper
• An assay for measuring functional activated thrombin-activatable fibrinolysis inhibitor in plasma.

  2008cited by this paper
• Thrombin-activable Fibrinolysis Inhibitor Zymogen Does Not Play a Significant Role in the Attenuation of Fibrinolysis*

  2008cited by this paper
• A functional assay for measuring activated thrombin-activatable fibrinolysis inhibitor in plasma.

  2004cited by this paper
• Enhanced in vitro procoagulant and antifibrinolytic potential of superactive variants of recombinant factor VIIa in severe hemophilia A

  2003cited by this paper
• Thrombin functions during tissue factor-induced blood coagulation.

  2002cited by this paper
• Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A.

  2002cited by this paper
• Overall haemostatic potential can be used for estimation of thrombin‐activatable fibrinolysis inhibitor‐dependent fibrinolysis in vivo and for possible follow‐up of recombinant factor VIIa treatment in patients with inhibitors to factor VIII

  2002cited by this paper
• Total thrombin‐activatable fibrinolysis inhibitor (TAFI) antigen and pro‐TAFI in patients with haemophilia A

  2001cited by this paper
• Milder clinical presentation of haemophilia A with severe deficiency of factor VIII as measured by one‐stage assay

  2001cited by this paper
• The Defective Down Regulation of Fibrinolysis in Haemophilia A Can Be Restored by Increasing the TAFI Plasma Concentration

  2001cited by this paper
• Platelets and Phospholipids in Tissue Factor-initiated Thrombin Generation

  2001cited by this paper
• The hemophilias--from royal genes to gene therapy.

  2001cited by this paper
• CPR‐Total (TAFI and Activated TAFI) Levels in Plasma/Serum of Hemophiliacs

  2000cited by this paper
• Roles of Thermal Instability and Proteolytic Cleavage in Regulation of Activated Thrombin-activable Fibrinolysis Inhibitor*

  2000cited by this paper
• The Molecular Weights, Mass Distribution, Chain Composition, and Structure of Soluble Fibrin Degradation Products Released from a Fibrin Clot Perfused with Plasmin*

  1999cited by this paper
• Blood coagulation in hemophilia A and hemophilia C.

  1998cited by this paper
• A Study of the Mechanism of Inhibition of Fibrinolysis by Activated Thrombin-activable Fibrinolysis Inhibitor*

  1998cited by this paper
• Evaluation of the Initiation Phase of Blood Coagulation Using Ultrasensitive Assays for Serine Proteases*

  1997cited by this paper
• Production and Characterization of Recombinant Human Plasminogen(S741C-Fluorescein)

  1997cited by this paper
• Blood clotting in minimally altered whole blood.

  1996cited by this paper
• Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma.

  1996cited by this paper
• Purification and Characterization of TAFI, a Thrombin-activable Fibrinolysis Inhibitor (*)

  1995cited by this paper
• A longitudinal study of orthopaedic outcomes for severe factor‐VIII‐deficient haemophiliacs

  1994cited by this paper
• Extrinsic pathway proteolytic activity.

  1993cited by this paper
• Surface-dependent reactions of the vitamin K-dependent enzyme complexes.

  1990cited by this paper
• Molecular pathology and immunology of factor VIII (hemophilia A and factor VIII inhibitors).

  1987cited by this paper
• Occult hemophilia.

  1980cited by this paper
• Hageman factor fragment inhibitor in corn seeds: purification and characterization.

  1980cited by this paper

• Profibrinolytic effects of rivaroxaban are mediated by thrombin-activatable fibrinolysis inhibitor and are attenuated by a naturally occurring stabilizing mutation in enzyme

  2023cites this paper
• In vitro effects of emicizumab on activated clotting time in blood samples from cardiac surgical patients

  2021cites this paper
• Comprehensive blood coagulation potential in patients with acquired hemophilia A: retrospective analyses of plasma samples obtained from nationwide centers across Japan

  2021cites this paper
• Fibrin(ogen) as a Therapeutic Target: Opportunities and Challenges

  2021cites this paper
• Heterogeneity in Bleeding Tendency and Arthropathy Development in Individuals with Hemophilia

  2021cites this paper
• MICROPARTICLES IN HEMOPHILIA – FRIEND OR FOE? – TO IMPROVE HEMOSTASIS OR TO INDUCE ATHEROTHROMBOSIS?

  2020cites this paper
• Red blood cells modulate structure and dynamics of venous clot formation in sickle cell disease.

  2019cites this paper
• Thrombin activatable fibrinolysis inhibitor pathway alterations correlate with bleeding phenotype in patients with severe hemophilia A

  2019cites this paper
• TAFI deficiency causes maladaptive vascular remodeling after hemophilic joint bleeding.

  2019cites this paper
• Evaluation of EC50 of factor VIII as predictor of prophylaxis efficacy in patients with severe haemophilia A

  2019cites this paper
• Fibrinolysis and Antifibrinolytics

  2018cites this paper
• Abrogating fibrinolysis does not improve bleeding or rFVIIa/rFVIII treatment in a non‐mucosal venous injury model in haemophilic rodents

  2018cites this paper
• Absence of functional compensation between coagulation factor VIII and plasminogen in double-knockout mice.

  2018cites this paper
• Defective TAFI activation in hemophilia A mice is a major contributor to joint bleeding.

  2018cites this paper
• Category : Thrombosis and Hemostasis Defective TAFI activation in hemophilia A mice is a major contributor to joint bleeding Running title : Defective TAFI activation in hemophilia A

  2018cites this paper
• Cardioprotection by Bioactive Polyphenols: A Strategic View

  2018cites this paper
• Cardioprotection by Bioactive Polyphenols: A Strategic View

  2018cites this paper
• Global assays of fibrinolysis

  2017cites this paper
• Global assays of fibrinolysis

  2017cites this paper
• Reduced fibrinolytic resistance in patients with factor XI deficiency. Evidence of a thrombin‐independent impairment of the thrombin‐activatable fibrinolysis inhibitor pathway

  2016cites this paper
• [Basic carboxypeptidases of blood: significance for coagulology].

  2016cites this paper
• Anti-fibrinolytic agents in bleeding disorders – A clinical perspective

  2016cites this paper
• Light‐chain amyloidosis presenting as a change in bleeding phenotype in a patient with mild haemophilia A

  2015cites this paper
• Phenotypic Heterogeneity of Hemostasis in Severe Hemophilia

  2015cites this paper
• Tranexamic acid as adjunct therapy to bypassing agents in haemophilia A patients with inhibitors

  2014cites this paper
• Co-administration of low molecular weight heparin enhances the profibrinolytic effect of warfarin through different mechanisms.

  2014cites this paper
• An in-vitro assessment of tranexamic acid as an adjunct to rFVIII or rFVIIa treatment in haemophilia A

  2014cites this paper
• Clinical Application of Fibrinolytic Assays

  2014cites this paper
• FXIII: mechanisms of action in the treatment of hemophilia A

  2014cites this paper
• Clot lysis phenotype and response to recombinant factor VIIa in plasma of haemophilia A inhibitor patients

  2013cites this paper
• Thrombin Activatable Fibrinolysis Inhibitor: A Putative Target to Enhance Fibrinolysis

  2013cites this paper
• Thrombin activatable fibrinolysis inhibitor: at the nexus of fibrinolysis and inflammation.

  2012cites this paper